Vitrakvi, or larotrectinib, received FDA accelerated approval for treatment of solid tumors with a specific genetic mutation regardless of the type of cancer. "We support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients," said Scott Gottlieb, FDA commissioner.
FDA grants accelerated approval to targeted genetic cancer treatment
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.